June 2025 has arrived, the future may be immunological We are June 12, 2025. INmune Bio is going quiet . The pieces of the inflammatory...

Introduction The $10 billion unicorn in INMB. I came up with that right after the Phase 1 results. If the title of these blogs felt like...

Summary The previous blog post discussed the history of drugs targeting amyloid and how commercialization in the Alzheimer’s space is...

Aloïs Alzheimer, 1915 Summary Amyloid aggregates and phosphorylated tau were the traditional hallmarks of Alzheimer’s disease. Efforts...

Introduction Novel biomarkers are changing the field drastically. They allow a view into the brain, whether through PET, MRI or...

One motor neuron, two microglia, and two astrocytes. (c) NeuroWoodworks.com , reproduced with authorization. https://x.com/NeuroWoodworks...

Introduction INmune Bio (INMB) is developing a novel therapy targeting neurodegenerative diseases, particularly Alzheimer’s disease (AD)....

Introduction INmune Bio (INMB) is developing a novel therapy targeting neurodegenerative diseases, particularly Alzheimer’s disease (AD)....

Summary " Scientists have found new solution for the treatment of Alzheimer’s disease. " The media coverage of preclinical discoveries or...

Stephen Bogle, an incoming Masters of Financial Economics candidate at the University of Toronto publishing under ‘Paurana Capital’ [1] ,...

Summary Alzheimer’s is a disease of slowly fading cognition. If you would ask me how much my grandmother’s Alzheimer’s progressed over...

Summary BioVie always argued that it saw a correlation between effects on cognition and reduction of TNF levels. That TNF reduction...

Introduction Amyloid beta has been the primary hallmark of Alzheimer’s disease for years. On the one hand, numerous trials focusing on...

Introduction Science journalist Charles Piller wrote a book, called ‘Doctored: fraud, arrogance, and tragedy in the quest to cure...

Introduction For years, the scientific focus may have been too focused on targeting amyloid, while inflammation and modulation of glial...

Summary INmune Bio is making significant strides across multiple programs, positioning itself as a major player in biotech. CORDstrom...

Summary Coverage of the Alzheimer’s space would be incomplete without a blog post on Cassava Sciences. Now was the right time. Cassava...

On JLO, RFK, the NIH, TNF, Karl Herrup and innovation - a longer post.   Summary The amyloid hypothesis did not yield the desired...

Summary I had a call with some investors earlier this week. During the call, the theme of accelerated approval came up. I had done a blog...

Historical failure rate of therapies targeting amyloid Alzheimer’s is characterized by aggregation of anti-amyloid antibodies and...